发明名称 PHARMACEUTICAL COMPOSITIONS OF 5,7,14-TRIAZATETRACYCLO[10.3.1.0(2,11).0(4,9)]-HEXADECA-2(11)3,5,7,9-PENTAENE
摘要 <p>The present invention is directed to controlled-release (CR) oral pharmaceutical dosage forms of 5,8,14-triazatetracyclo[10.3.1.0<2,11>.0<4,9>]-hexadeca-2(11 ),3,5,7,9-pentaene, 1, and pharmaceutically acceptable salts thereof, and methods of using them to reduce nicotine addiction or aiding in the cessation or lessening of tobacco use while reducing nausea as an adverse effect. The present invention also relates to an immediate-release (IR) low dosage composition having a stable formulation with uniform drug distribution and potency.</p>
申请公布号 WO03045437(A8) 申请公布日期 2003.08.14
申请号 WO2002IB04612 申请日期 2002.11.04
申请人 PFIZER PRODUCTS INC.;AM ENDE, MARY, TANYA;ROY, MICHAEL, CHRISTOPHER;SMITH, SCOTT, WENDELL;WATERMAN, KENNETH, CRAIG;MOSES, SARA, KRISTEN;QUAN, ERNEST, SHING 发明人 AM ENDE, MARY, TANYA;ROY, MICHAEL, CHRISTOPHER;SMITH, SCOTT, WENDELL;WATERMAN, KENNETH, CRAIG;MOSES, SARA, KRISTEN;QUAN, ERNEST, SHING
分类号 A61K9/22;A61K9/20;A61K9/26;A61K9/28;A61K31/495;A61K31/4985;A61K47/02;A61K47/10;A61K47/34;A61K47/36;A61K47/38;A61P1/00;A61P1/04;A61P3/04;A61P9/00;A61P9/10;A61P9/12;A61P25/02;A61P25/06;A61P25/14;A61P25/16;A61P25/18;A61P25/20;A61P25/22;A61P25/24;A61P25/28;A61P25/30;A61P25/32;A61P25/34;A61P25/36;A61P37/02;(IPC1-7):A61K47/38 主分类号 A61K9/22
代理机构 代理人
主权项
地址